Mercados españoles cerrados

argenx SE (ARGX.BR)

Brussels - Brussels Precio demorado. Divisa en EUR
Añadir a la lista de favoritos
425,70+2,30 (+0,54%)
Al cierre: 05:35PM CEST

argenx SE

Laarderhoogtweg 25
Amsterdam 1101EB
Netherlands
31 10 703 8441
https://www.argenx.com

Sector(es)Healthcare
SectorBiotechnology
Empleados a tiempo completo1148

Ejecutivos clave

NombreTítuloPagaEjecutadoAño de nacimiento
Mr. Timothy Van Hauwermeiren EMBA, M.Sc.CEO & Executive Director1,18MN/A1972
Mr. Karl GubitzChief Financial Officer773,51kN/A1970
Ms. Karen MasseyChief Operating Officer1,3MN/A1979
Mr. Filip BorgionsVP & Global Head of Technical OperationsN/AN/AN/A
Mr. Peter UlrichtsChief Scientific OfficerN/AN/A1980
Ms. Beth DelGiaccoVP and Global Head of Corporate Communications & Investor RelationsN/AN/AN/A
Ms. Malini MoorthyGeneral CounselN/AN/A1970
Mr. Arjen Lemmen M.Sc.Vice President of Corporate Development & StrategyN/AN/A1985
Mr. Marc SchorpionGlobal Head of Human ResourcesN/AN/A1959
Ms. Andria WilkGlobal Head of QualityN/AN/A1974
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Paga es el salario, las bonificaciones, etc. Ejecutado es el valor de las opciones ejecutadas durante el año fiscal. Divisa en EUR.

Descripción

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Gobierno corporativo

El ISS Governance QualityScore de argenx SE, a día 1 de julio de 2024, es 5. Las puntuaciones base son Auditoría: 3; Tablero: 2; Derechos de los accionistas: 3; Compensación: 10.

Puntuación de gobierno corporativo cedida por Institutional Shareholder Services (ISS). Las puntuaciones indican un rango decil relativo al índice o región. Una puntuación decil de 1 indica un menor riesgo de gobierno, mientras que un 10 indica un riesgo de gobierno superior.